Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Split-dose pazopanib exposure study
NL-OMON45488Phase 4Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pazopanib in renal cell carcinoma (RCC) and soft tissue sarcoma (STS), sponsored by Netherlands Cancer Institute. Primary endpoints: Increase in pazopanib Cmin and Increase in pazopanib AUC0-24h. Started Jan 2018; status: active, not recruiting.
02
Drugs
pazopanib
03
Conditions
renal cell carcinoma (RCC)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NL-OMON45488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45488.